EMA Authorised: Kaftrio (ivacaftor;tezacaftor;elexacaftor) — Vertex Pharmaceuticals (Ireland) Limited

View source ↗

Summary

The EMA authorised Kaftrio, a fixed-dose triple combination of ivacaftor, tezacaftor and elexacaftor, for cystic fibrosis, with orphan designation. Decision dat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Kaftrio (elexacaftor/tezacaftor/ivacaftor)

Snippet

Status: Authorised. Therapeutic area: Cystic Fibrosis. MAH: Vertex Pharmaceuticals (Ireland) Limited. Decision date: 18/03/2026. Orphan medicine